Biodegradable drug-eluting stents: targeting urothelial tumors of upper urinary tract

Urothelial tumors of upper urinary tract are ranked among the most common types of cancers worldwide. The current standard therapy to prevent recurrence is intravesical Bacillus-Calmetteâ Guerin (BCG) immunotherapy, but it presents several disadvantages such as BCG failure and intolerance. Another w...

Full description

Bibliographic Details
Main Author: Barros, Alexandre António Antunes (author)
Other Authors: Browne, S. (author), Oliveira, C. (author), Reis, R. L. (author), Duarte, Ana Rita C. (author), Healy, K. E. (author), Lima, Estêvão Augusto Rodrigues de (author)
Format: conferenceObject
Language:eng
Published: 2016
Subjects:
Biodegrable
Drug-eluting
Stents
Urothelial cancer
Online Access:http://hdl.handle.net/1822/42046
Country:Portugal
Oai:oai:repositorium.sdum.uminho.pt:1822/42046
Description
Summary:Urothelial tumors of upper urinary tract are ranked among the most common types of cancers worldwide. The current standard therapy to prevent recurrence is intravesical Bacillus-Calmetteâ Guerin (BCG) immunotherapy, but it presents several disadvantages such as BCG failure and intolerance. Another way is to use chemotherapy, which is generally better tolerated that BCG. In this case, drugs such as epirubicin, doxorubicin, paclitaxel and gemcitabine are used. Nevertheless, intravesical chemotherapy only prevents recurrence in the short-term.

Similar Items